Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Reduced turnaround time and improved diagnosis of invasive serogroup B Neisseria meningitidis and Streptococcus pneumoniae infections using a lyophilized quadruplex quantitative PCR.

McHugh MP, Gray SJ, Kaczmarski EB, Guiver M.

J Med Microbiol. 2015 Nov;64(11):1321-8. doi: 10.1099/jmm.0.000154. Epub 2015 Aug 5.

PMID:
26253287
2.

Investigation into the Antigenic Properties and Contributions to Growth in Blood of the Meningococcal Haemoglobin Receptors, HpuAB and HmbR.

Bidmos FA, Chan H, Praekelt U, Tauseef I, Ali YM, Kaczmarski EB, Feavers I, Bayliss CD.

PLoS One. 2015 Jul 24;10(7):e0133855. doi: 10.1371/journal.pone.0133855. eCollection 2015.

3.

MBL2 deficiency is associated with higher genomic bacterial loads during meningococcemia in young children.

Darton TC, Jack DL, Johnson M, Borrow R, Guiver M, Kaczmarski EB, Turner MW, Klein NJ, Read RC.

Clin Microbiol Infect. 2014 Dec;20(12):1337-42. doi: 10.1111/1469-0691.12745. Epub 2014 Dec 18.

4.

The distribution and 'in vivo' phase variation status of haemoglobin receptors in invasive meningococcal serogroup B disease: genotypic and phenotypic analysis.

Lucidarme J, Findlow J, Chan H, Feavers IM, Gray SJ, Kaczmarski EB, Parkhill J, Bai X, Borrow R, Bayliss CD.

PLoS One. 2013 Sep 30;8(9):e76932. doi: 10.1371/journal.pone.0076932. eCollection 2013.

5.

Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.

Lucidarme J, Gilchrist S, Newbold LS, Gray SJ, Kaczmarski EB, Richardson L, Bennett JS, Maiden MC, Findlow J, Borrow R.

Clin Vaccine Immunol. 2013 Sep;20(9):1360-9. doi: 10.1128/CVI.00090-13. Epub 2013 Jun 26.

6.

Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.

Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, Mallard RH, Guiver M, Newbold LS, Borrow R.

Vaccine. 2012 May 21;30(24):3710-6. doi: 10.1016/j.vaccine.2012.03.011. Epub 2012 Mar 17.

PMID:
22429756
7.

Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009.

Ladhani SN, Lucidarme J, Newbold LS, Gray SJ, Carr AD, Findlow J, Ramsay ME, Kaczmarski EB, Borrow R.

Emerg Infect Dis. 2012 Jan;18(1):63-70. doi: 10.3201/eid1801.110901.

8.

Bacterial genomic detection within cerebrospinal fluid of patients with meningococcal disease is influenced by microbial and host characteristics.

Darton TC, Guiver M, Naylor S, Kaczmarski EB, Borrow R, Read RC.

Clin Infect Dis. 2011 Sep;53(5):463-7. doi: 10.1093/cid/cir433. Epub 2011 Jul 27.

PMID:
21798855
9.

Usefulness of porA sequencing in distinguishing sporadic and linked cases of serogroup B invasive meningococcal disease in Suffolk, United Kingdom, December 2009 to January 2010.

Varadarajan A, Sundkvist T, Jayatilleke N, Williams C, Gray SJ, Carr AD, Kaczmarski EB.

Euro Surveill. 2011 Jan 27;16(4). pii: 19775.

10.

Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP.

Lucidarme J, Newbold LS, Findlow J, Gilchrist S, Gray SJ, Carr AD, Hewitt J, Kaczmarski EB, Borrow R.

Clin Vaccine Immunol. 2011 Feb;18(2):194-202. doi: 10.1128/CVI.00401-10. Epub 2010 Dec 1.

11.

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.

Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R.

Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7.

12.

Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales.

Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Kugelberg E, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Tang CM, Borrow R.

J Clin Microbiol. 2009 Nov;47(11):3577-85. doi: 10.1128/JCM.00936-09. Epub 2009 Sep 16.

13.

The tumor necrosis factor polymorphism TNF (-308) is associated with susceptibility to meningococcal sepsis, but not with lethality.

Read RC, Teare DM, Pridmore AC, Naylor SC, Timms JM, Kaczmarski EB, Borrow R, Wilson AG.

Crit Care Med. 2009 Apr;37(4):1237-43. doi: 10.1097/CCM.0b013e31819c39bc.

PMID:
19242354
14.

Severity of meningococcal disease associated with genomic bacterial load.

Darton T, Guiver M, Naylor S, Jack DL, Kaczmarski EB, Borrow R, Read RC.

Clin Infect Dis. 2009 Mar 1;48(5):587-94. doi: 10.1086/596707.

PMID:
19191644
15.

Association of a bacteriophage with meningococcal disease in young adults.

Bille E, Ure R, Gray SJ, Kaczmarski EB, McCarthy ND, Nassif X, Maiden MC, Tinsley CR.

PLoS One. 2008;3(12):e3885. doi: 10.1371/journal.pone.0003885. Epub 2008 Dec 9.

16.

Opa protein repertoires of disease-causing and carried meningococci.

Callaghan MJ, Buckee C, McCarthy ND, Ibarz Pavón AB, Jolley KA, Faust S, Gray SJ, Kaczmarski EB, Levin M, Kroll JS, Maiden MC, Pollard AJ.

J Clin Microbiol. 2008 Sep;46(9):3033-41. doi: 10.1128/JCM.00005-08. Epub 2008 May 28.

17.

Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease.

Jack DL, Cole J, Naylor SC, Borrow R, Kaczmarski EB, Klein NJ, Read RC.

Clin Infect Dis. 2006 Dec 1;43(11):1426-33. Epub 2006 Oct 31.

PMID:
17083016
19.

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

Meningococcal Reference Unit, Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH, Kaczmarski EB.

J Med Microbiol. 2006 Jul;55(Pt 7):887-96.

PMID:
16772416
20.

Multilocus sequence typing of Neisseria meningitidis directly from clinical samples and application of the method to the investigation of meningococcal disease case clusters.

Birtles A, Hardy K, Gray SJ, Handford S, Kaczmarski EB, Edwards-Jones V, Fox AJ.

J Clin Microbiol. 2005 Dec;43(12):6007-14.

21.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME.

Lancet. 2004 Jul 24-30;364(9431):365-7.

PMID:
15276396
22.

Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?

Davison KL, Andrews N, White JM, Ramsay ME, Crowcroft NS, Rushdy AA, Kaczmarski EB, Monk PN, Stuart JM.

Arch Dis Child. 2004 Mar;89(3):256-60.

23.

Measurement and interpretation of pneumococcal IgG levels for clinical management.

Balmer P, North J, Baxter D, Stanford E, Melegaro A, Kaczmarski EB, Miller E, Borrow R.

Clin Exp Immunol. 2003 Sep;133(3):364-9.

24.

Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease.

Read RC, Cannings C, Naylor SC, Timms JM, Maheswaran R, Borrow R, Kaczmarski EB, Duff GW.

Ann Intern Med. 2003 Apr 1;138(7):534-41.

PMID:
12667023
25.

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.

Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E.

BMJ. 2003 Feb 15;326(7385):365-6. No abstract available.

26.

Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin.

Trotter CL, Fox AJ, Ramsay ME, Sadler F, Gray SJ, Mallard R, Kaczmarski EB.

J Med Microbiol. 2002 Oct;51(10):855-60.

PMID:
12435065
27.

Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.

Trotter CL, Ramsay ME, Kaczmarski EB.

Commun Dis Public Health. 2002 Sep;5(3):220-5.

PMID:
12434692
28.

Estimating the burden of serogroup C meningococcal disease in England and Wales.

Davison KL, Ramsay ME, Crowcroft NS, Lieftucht A, Kaczmarski EB, Trotter CL, Gungabissoon U, Begg NT.

Commun Dis Public Health. 2002 Sep;5(3):213-9.

PMID:
12434691
29.

Enhanced surveillance scheme for suspected meningococcal disease in five regional health authorities in England: 1998.

Davison KL, Crowcroft NS, Ramsay ME, Begg NT, Kaczmarski EB, Stuart JM, White JM, Orr H; Enhanced Surveillance of Meningococcal Disease Project Group.

Commun Dis Public Health. 2002 Sep;5(3):205-12. Erratum in: Commun Dis Public Health. 2002 Dec;5(4):343..

PMID:
12434690
30.

Development and evaluation of a 'real-time' RT-PCR for the detection of enterovirus and parechovirus RNA in CSF and throat swab samples.

Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB, Mutton KJ.

J Med Virol. 2002 Aug;67(4):555-62.

PMID:
12116004
31.

Improved case confirmation in meningococcal disease with whole blood Taqman PCR.

Hackett SJ, Carrol ED, Guiver M, Marsh J, Sills JA, Thomson AP, Kaczmarski EB, Hart CA.

Arch Dis Child. 2002 Jun;86(6):449-52.

32.

W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001.

Hahné SJ, Gray SJ, Jean-François, Aguilera, Crowcroft NS, Nichols T, Kaczmarski EB, Ramsay ME.

Lancet. 2002 Feb 16;359(9306):582-3.

PMID:
11867116
33.

Ultrasound enhanced detection of individual meningococcal serogroups by latex immunoassay.

Sobanski MA, Vince R, Biagini GA, Cousins C, Guiver M, Gray SJ, Kaczmarski EB, Coakley WT.

J Clin Pathol. 2002 Jan;55(1):37-40.

34.

Meningococcal bacterial DNA load at presentation correlates with disease severity.

Hackett SJ, Guiver M, Marsh J, Sills JA, Thomson AP, Kaczmarski EB, Hart CA.

Arch Dis Child. 2002 Jan;86(1):44-6.

35.

Risk of laboratory-acquired meningococcal disease.

Boutet R, Stuart JM, Kaczmarski EB, Gray SJ, Jones DM, Andrews N.

J Hosp Infect. 2001 Dec;49(4):282-4.

PMID:
11740877
36.

Prevention of meningococcal infection in laboratory workers--an audit of practice in England and Wales.

Boutet R, Stuart JM, Jones DM, Kaczmarski EB.

Commun Dis Public Health. 2001 Jun;4(2):130-2.

PMID:
11525001
37.

Preventing secondary meningococcal disease in health care workers: recommendations of a working group of the PHLS meningococcus forum.

Stuart JM, Gilmore AB, Ross A, Patterson W, Kroll JS, Kaczmarski EB, MacQueen S, Keady P, Monk P; PHLS Communicable Disease Surveillance Center.

Commun Dis Public Health. 2001 Jun;4(2):102-5.

PMID:
11524996
38.

A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease.

Read RC, Pullin J, Gregory S, Borrow R, Kaczmarski EB, di Giovine FS, Dower SK, Cannings C, Wilson AG.

J Infect Dis. 2001 Sep 1;184(5):640-2. Epub 2001 Jul 30.

PMID:
11494169
39.
40.

Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Ramsay ME, Andrews N, Kaczmarski EB, Miller E.

Lancet. 2001 Jan 20;357(9251):195-6.

PMID:
11213098
41.

Meningococcal serology.

Gray SJ, Borrow R, Kaczmarski EB.

Methods Mol Med. 2001;67:61-87. doi: 10.1385/1-59259-149-3:61.

PMID:
21337138
42.

Improved methods of detection of meningococcal DNA from oropharyngeal swabs from cases and contacts of meningococcal disease.

Sadler F, Borrow R, Dawson MM, Kaczmarski EB, Cartwright K, Fox AJ.

Epidemiol Infect. 2000 Oct;125(2):277-83.

43.

An interleukin-1 genotype is associated with fatal outcome of meningococcal disease.

Read RC, Camp NJ, di Giovine FS, Borrow R, Kaczmarski EB, Chaudhary AG, Fox AJ, Duff GW.

J Infect Dis. 2000 Nov;182(5):1557-60. Epub 2000 Oct 9.

PMID:
11023482
44.

Carriage of Neisseria meningitidis in residents and staff at a residential home for elderly people following a case of invasive disease.

Irwin DJ, Crawshaw JG, Readman RA, Teare L, Kaczmarski EB.

Commun Dis Public Health. 2000 Sep;3(3):172-4.

PMID:
11014028
45.

Performance characteristics of the polymerase chain reaction assay to confirm clinical meningococcal disease.

Carrol ED, Thomson AP, Shears P, Gray SJ, Kaczmarski EB, Hart CA.

Arch Dis Child. 2000 Sep;83(3):271-3.

46.
47.

Measurement of serum antigen concentration by ultrasound-enhanced immunoassay and correlation with clinical outcome in meningococcal disease.

Sobanski MA, Barnes RA, Gray SJ, Carr AD, Kaczmarski EB, O'Rourke A, Murphy K, Cafferkey M, Ellis RW, Pidcock K, Hawtin P, Coakley WT.

Eur J Clin Microbiol Infect Dis. 2000 Apr;19(4):260-6.

PMID:
10834814
48.

Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA.

Guiver M, Borrow R, Marsh J, Gray SJ, Kaczmarski EB, Howells D, Boseley P, Fox AJ.

FEMS Immunol Med Microbiol. 2000 Jun;28(2):173-9.

49.

Contamination and sensitivity issues with a real-time universal 16S rRNA PCR.

Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kaczmarski EB, Fox AJ.

J Clin Microbiol. 2000 May;38(5):1747-52.

50.

Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.

Borrow R, Richmond P, Kaczmarski EB, Iverson A, Martin SL, Findlow J, Acuna M, Longworth E, O'Connor R, Paul J, Miller E.

FEMS Immunol Med Microbiol. 2000 May;28(1):79-85.

Supplemental Content

Loading ...
Support Center